Delta Dore, entreprise de gestion de l’énergie dans les logements, noue un partenariat stratégique avec Survoltage, opérateur de flexibilité agréé RTE. Ensemble, ils lancent SmartFlow, une solution d’effacement à destination des particuliers.

Reported Thursday, Sep 17 - 9:24am EDT (TheFly subscription required to read more.)

Keeping its foot on the innovation pedal has been central to strong growth at water technology company SmartFlow

Descriptive, non-directional summary of recent AI analyses.

Nuwellis (Nasdaq: NUWE) announced a digital transformation program for its Aquadex SmartFlow® System to position it as a connected extracorporeal therapy platform for intensive care settings. The initiative uses Philips Capsule™ interoperability technology and a next-generation tablet-based user interface to enhance EHR connectivity and clinician workflow.The program comprises integration with leading electronic health record systems so Aquadex therapy data can flow automatically into patient records, and a modern UI to display key therapy and device status information. According to Nuwellis, these research-stage enhancements are not yet FDA approved and are not available for commercial or clinical use.

Nuwellis (Nasdaq: NUWE) announced strategic development initiatives to evolve its Aquadex SmartFlow® System from a focused ultrafiltration device into a broader extracorporeal therapy platform. The program aims to support higher blood flow rates, expanded pressure ranges, and compatibility with advanced therapies such as immunomodulation, blood purification, and extracorporeal life support.According to Nuwellis, this research-stage effort is intended to expand its long-term addressable market and enable collaborations with developers of extracorporeal therapies. The company emphasized that these new applications are in development, are not FDA-approved, and are not available for commercial sale or clinical use.

Descriptive, non-directional summary of recent AI analyses.

ClearPoint Neuro (Nasdaq: CLPT) congratulated partner Aspen Neuroscience on receiving U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for sasineprocel (ANPD001), an investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease. RMAT status is based on preliminary clinical evidence and does not constitute approval.According to ClearPoint Neuro, its Navigation System and SmartFlow Cannula are being used for cell transplantation in Aspen's ASPIRO clinical trial in moderate to severe Parkinson's disease. ClearPoint reports supporting 60+ biologics and drug delivery partner programs, with over 10 having received one or more expedited regulatory review designations.

Nuwellis announced the installation of its Aquadex SmartFlow ultrafiltration systems at a leading pediatric healthcare institution in Wisconsin, marking entry into a new Midwest market. Separately, the company disclosed that Frontiers in Pediatrics accepted publication of a study evaluating Epoprostenol as an alternative anticoagulant during Aquadex therapy in critically ill children.

Nuwellis (Nasdaq: NUWE) announced its entry into Wisconsin’s pediatric critical care market through the first installations of its Aquadex SmartFlow® systems at a leading pediatric academic medical center. The collaboration aims to build clinical pathways and integrate Aquadex therapy into the hospital’s pediatric program.The company continues to focus on pediatric and critical care expansion, targeting fluid-overloaded patients unresponsive to diuretics and weighing 20 kilograms or more. Nuwellis recently completed a pre-submission meeting with the FDA on expanding the Aquadex label to patients 5 kilograms and above and anticipates a 510(k) submission by the end of 2026.